Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists
Open accessThe DOI matches its Crossref record; 236 of the 237 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
The protein p53, known as the “Guardian of the Genome”, plays an important role in maintaining DNA integrity, providing protection against cancer-promoting mutations. Dysfunction of p53 is observed in almost every cancer, with 50% of cases bearing loss-of-function mutations/deletions in the TP53 gene. In the remaining 50% of cases the overexpression of HDM2 (mouse double minute 2, human homolog) protein, which is a natural inhibitor of p53, is the most common way of keeping p53 inactive. Disruption of HDM2-p53 interaction with the use of HDM2 antagonists leads to the release of p53 and expression of its target genes, engaged in the induction of cell cycle arrest, DNA repair, senescence, and apoptosis. The induction of apoptosis, however, is restricted to only a handful of p53wt cells, and, generally, cancer cells treated with HDM2 antagonists are not efficiently eliminated. For this reason, HDM2 antagonists were tested in combinations with multiple other therapeutics in a search for synergy that would enhance the cancer eradication. This manuscript aims at reviewing the recent progress in developing strategies of combined cancer treatment with the use of HDM2 antagonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“According to these three clear binding sites, a variety of structural types of MDM2 inhibitors have been reported, among which nine have entered clinical trials (RG7112, RG7388/RO6839921, MK-8242, AMG232, SAR405838, DS-3032b, HDM201, NVP-CGM097 and APG-115) (Fig. 3), with a variety of scaffold types [15–18].”
From Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials (2022) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, MDM2 inhibitors sensitize cells to a range of other therapies, including radiation, thus enhancing response to standard-of-care therapy for GBM (6).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“MDM2 inhibitors can enhance response to both radiation therapy (RT) and temozolomide,7-9 the standard of care for GBM.”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [8]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 1×
“Direct DNA damage is caused by the introduction of DNA strand breaks, while indirect is mediated by the production of reactive oxygen species (ROS), which in turn lead to many DNA modifications like formation of abasic sites, DNA adducts, single-strand breaks (SSBs) and double-strand breaks (DSBs), DNA-protein crossli…”
BackgroundCisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537 · cited 2×
“This forms monofunctional adducts or inter-strand, intra-strand, or DNA-protein crosslinks [127].”
BackgroundThe resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717 · cited 1×
“Platinum complexes are molecules that form covalent links between DNA nucleobases, bridged by the platinum atom-containing moieties (a mechanism similar to that of alkylating agents) [126].”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“One of the earliest HDM2 antagonists, discovered by Hoffman-La Roche (Basel, Switzerland) in the early 21st century, are called the nutlins and are built around the cis-imidazoline core [113].”
BackgroundTumor suppressor p53 is a direct transcriptional activator of the human bax gene
Toshiyuki, M., & Reed, J. C. (1995) · Cell · doi:10.1016/0092-8674(95)90412-3 · Cited by 4,063 · cited 1×
“This version of p53 results in the induction of apoptosis at least partially by the activation of a positive p53-PTEN (phosphatase and tensin homolog deleted on chromosome ten)-Akt-HDM2 loop [23] and induction of the expression of pro-apoptotic Bax protein [24].”
BackgroundDu, C., Fang, M., Li, Y., Li, L., & Wang, X. (2000) · Cell · doi:10.1016/s0092-8674(00)00008-8 · Cited by 3,513
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,416 · cited 2×
“ABT-737 is a BH3 inhibitor of BCL-2, BCL-XL, and BCL-W proteins [151,152].”
BackgroundABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“Many studies indicate that ionizing radiation and chemotherapy work better on wild-type p53 tumors [223].”
BackgroundIdentification and characterization of a new member of the TNF family that induces apoptosis
Wiley, S. R., Schooley, K., Smolak, P. J., Din, W. S., Huang, C.-P., Nicholl, J. K., Sutherland, G. R., Smith, T. D., Rauch, C., Smith, C. A., et al. (1995) · Immunity · doi:10.1016/1074-7613(95)90057-8 · Cited by 2,900
Cited by
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Zhu, H., Gao, H., Ji, Y., Zhou, Q., Du, Z., Tian, L., Jiang, Y., Yao, K., & Zhou, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01314-3 · Cited by 223
Targeting apoptotic pathways for cancer therapy
Tian, X., Srinivasan, P. R., Tajiknia, V., Uruchurtu, A. S. S., Seyhan, A. A., Carneiro, B. A., Cruz, A. D. L., Pinho-Schwermann, M. P., George, A., Zhao, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci179570 · Cited by 173
“The first approach uses agents targeting p53-negative regulators to activate WT p53, such as MDM2 inhibitors (69, 70).”
Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells
Skalniak, L., Kocik, J., Polak, J., Skalniak, A., Rak, M., Wolnicka-Glubisz, A., & Holak, T. (2018) · Cancers · doi:10.3390/cancers10110396 · Cited by 73
Self-citationMDM2: current research status and prospects of tumor treatment
Yao, Y., Zhang, Q., Li, Z., & Zhang, H. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03356-8 · Cited by 83
“Safe dose intravenous injection of RO6839921 showed good anti-tumor activity in osteosarcoma and AML xenograft models [87].”
BackgroundTargeting the epigenome in in-stent restenosis: from mechanisms to therapy
Yang, X., Yang, Y., Guo, J., Meng, Y., Li, M., Yang, P., Liu, X., Aung, L. H. H., Yu, T., & Li, Y. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.01.024 · Cited by 61
Bata, N., & Cosford, N. D. P. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.1c00130 · Cited by 63
Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
Wu, C., Pan, Y., Yeh, C., & Lunec, J. (2020) · Biomolecules · doi:10.3390/biom10111474 · Cited by 49
MDM2/X inhibitors as radiosensitizers for glioblastoma targeted therapy
Miles, X., Vandevoorde, C., Hunter, A., & Bolcaen, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.703442 · Cited by 40
“In addition, therapeutic effects have been documented to be short-term due to acquired resistance or acquisition of p53 mutations (38, 107, 215).”
BackgroundA selective p53 activator and anticancer agent to improve colorectal cancer therapy
Ramos, H., Soares, M. I. L., Silva, J., Raimundo, L., Calheiros, J., Gomes, C. M. F., Reis, F., Monteiro, F. A., Nunes, C., Reis, S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.108982 · Cited by 43
“…compounds under clinical trials (Merkel et al., 2017), the Nutlins (NCT03566485, NCT02633059, NCT03566485; Phases I/II) are not active on mutp53 (Kocik et al., 2019), and PRIMA-1MET (APR-246; NCT03745716; Phase III) has a p53-independent inhibitory activ- (B) IC50 values of MANIO in a panel of…”
BackgroundDying to Survive—The p53 Paradox
Lees, A., Sessler, T., & McDade, S. S. (2021) · Cancers · doi:10.3390/cancers13133257 · Cited by 41
Kim, D., Min, D., Kim, J., Kim, J. M., Seo, Y., Jung, B. H., Kwon, S., Ro, H., Lee, S., Sa, J. K., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02922-8 · Cited by 31
“However, the number of studies on the effect of nutlin-3a in lung cancer cells is scarce; most studies show combinational effects with radio-or chemotherapy [31–33].”
BackgroundEmerging therapeutic targets for nasopharyngeal carcinoma: opportunities and challenges
Baloche, V. M. D., Ferrand, F., Makowska, A. M., Even, C., Kontny, U., & Busson, P. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1751820 · Cited by 31
“Combinations with other drugs are often required to induce a transition of the TP53 protein from its ‘arrester’ to ‘killer’ status, involving distinct phosphorylation events [95].”
BackgroundCompetition NMR for Detection of Hit/Lead Inhibitors of Protein–Protein Interactions
Musielak, B., Janczyk, W., Rodríguez, I., Plewka, J., Sala, D., Magiera‐Mularz, K., & Holak, T. A. (2020) · Molecules · doi:10.3390/molecules25133017 · Cited by 26
Self-citationShared Gene Targets of the ATF4 and p53 Transcriptional Networks
Baniulyte, G., Durham, S. A., Merchant, L. E., & Sammons, M. A. (2023) · Molecular and Cellular Biology · doi:10.1080/10985549.2023.2229225 · Cited by 20
“A second approach uses compounds like the MDM2 inhibitor nutlin-3A to activate wild-type p53 in a non-genotoxic fashion, although early clinical trials suggest these approaches have limited efficacy when used alone (Andreeff et al., 2016; Kocik et al., 2019; Montesinos et al., 2020).”
Harnessing p53 for targeted cancer therapy: new advances and future directions
Andrysík, Z., & Espinosa, J. M. (2025) · Transcription · doi:10.1080/21541264.2025.2452711 · Cited by 22
Bazanov, D. R., Pervushin, N. V., Savin, E. V., Tsymliakov, M. D., Maksutova, A. I., Sosonyuk, S. E., Kopeina, G. S., & Lozinskaya, N. A. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-021-02802-w · Cited by 18
“nutlins are commonly used in combinations with other chemotherapeutics [29].”
BackgroundLiu, W., Ma, Y., He, Y., Liu, Y., Guo, Z., He, J., Han, X., Hu, Y., Li, M., Jiang, R., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00784 · Cited by 20
Small-molecule modulation of p53 protein-protein interactions
Kuusk, A., Boyd, H., Chen, H., & Ottmann, C. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0405 · Cited by 18
Skayneh, H., Jishi, B., Hleihel, R., Hamie, M., Hajj, R. E., Deleuze‐Masquéfa, C., Bonnet, P., El-Sabban, M. E., & Hajj, H. E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073421 · Cited by 17
Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma
Landman, N., Hulsman, D., Badhai, J., Kopparam, J., Puppe, J., Pandey, G. K., & van Lohuizen, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02661-3 · Cited by 18
“Taken together, all this data warrants further research into the indirect link between BAP1 and ATM and how this might affect DSB repair, and facilitates the investigation for clinical possibilities of this combination strategy against BAP1-de fi cient mesothelioma.”
Cui, Y., Zhou, J., & Rong, F. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.09.135 · Cited by 14
Łasut-Szyszka, B., Gdowicz‐Kłosok, A., Małachowska, B., Krześniak, M., Będzińska, A., Gawin, M., Pietrowska, M., & Rusin, M. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.110946 · Cited by 14
Łasut-Szyszka, B., Gdowicz‐Kłosok, A., Krześniak, M., Głowala‐Kosińska, M., Będzińska, A., & Rusin, M. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02000-0 · Cited by 11
“Their therapeutic use is limited by their inefficiency in killing cancer cells – they mainly induce cell-cycle arrest [ 24 ].”
BackgroundThe p53 protein – not only the guardian of the genome
Rusin, M. (2024) · Postępy Biochemii · doi:10.18388/pb.2021_518 · Cited by 14
“In contrast, a quadruple mutant p53(25,26,53,54) that is com - pletely defective for transactivation, fails to suppress tumor formation [63].”
BackgroundWu, C., Ng, C. T., & Tan, K. T. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050357 · Cited by 7
Pervushin, N. V., Nilov, D. K., Pushkarev, S. V., Shipunova, V. O., Станиславовна, Б. А., Yapryntseva, M. A., Kopytova, D. V., Zhivotovsky, B., & Kopeina, G. S. (2024) · APOPTOSIS · doi:10.1007/s10495-024-02014-8 · Cited by 9
Targeting anti-apoptotic mechanisms in tumour cells: Strategies for enhancing Cancer therapy
Chaudhary, B., Arya, P., Sharma, V., Kumar, P., Singla, D., & Grewal, A. S. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108388 · Cited by 6
Vaubel, R. A., Zhang, W., Oh, J.-H., Mladek, A. C., Pasa, T. I., Gantchev, J. K., Waller, K. L., Baquer, G., Stopka, S. A., Regan, M. S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0244 · Cited by 2
Antibacterial Activity of the p53 Tumor Suppressor Protein—How Strong Is the Evidence?
Gdowicz‐Kłosok, A., Krześniak, M., Łasut-Szyszka, B., Butkiewicz, D., & Rusin, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094416 · Cited by 2
“This leads to the activation of p53 with all of its consequences [13].”
Krześniak, M., Łasut-Szyszka, B., Będzińska, A., Gdowicz‐Kłosok, A., & Rusin, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071449 · Cited by 1
“To find out if other antagonists of p53-MDM2 interaction have a similar impact on DUSP13 expression as nutlin-3a, we exposed A549 cells to idasanutlin or RG7112 (reviewed by Kocik et al. [26]) either alone or in combination with actinomycin D.”
BackgroundFerroptosis as a therapeutic vulnerability in MDM2 inhibition in dedifferentiated liposarcoma
Yen, C., Chen, P., Chen, S., Wu, W., Yen, C., Lin, Y., Wu, P., Chen, C.-M., Wang, J., Chao, T., et al. (2025) · Oncology Letters · doi:10.3892/ol.2025.15015 · Cited by 1
Nieznanska, A., Statkiewicz, M., Sandowska-Markiewicz, Z., Unrug-Bielawska, K., Majewska, A., Kocik-Krol, J., Czepiel, M., Gałuszka-Bulaga, A., Mikuła, M., Ostrowski, J., et al. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118868 · Cited by 1
Self-citationAn, H.-G., Shin, S., Lee, B., Kwon, Y., Kwon, T.-U., Kwon, Y., & Chun, Y. (2022) · Toxicological Research · doi:10.1007/s43188-022-00150-4 · Cited by 2
Small-Molecule Inhibitors of Protein–Protein Interactions as Therapeutics
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_7 · Cited by 1
Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259
Larasati (2020) · UWSpace (University of Waterloo) · Cited by 1
Molecular Landscape Profile of Melanoma
Palmieri, G., Colombino, M., Casula, M., Sini, M. C., Manca, A., Pisano, M., Paliogiannis, P., & Cossu, A. (2021) · Springer eBooks · doi:10.1007/978-3-030-64009-5_2 · Cited by 1
MDM2 inhibitors: Targeting p53-MDM2 interaction to anti-cancer
Zhang, X. (2021) · E3S Web of Conferences · doi:10.1051/e3sconf/202130802015
Krześniak, M., Łasut-Szyszka, B., Będzińska, A., Gdowicz‐Kłosok, A., & Rusin, M. (2023) · Preprints.org · doi:10.20944/preprints202309.1653.v1
Krześniak, M., Łasut-Szyszka, B., Będzińska, A., Gdowicz‐Kłosok, A., & Rusin, M. (2024) · Preprints.org · doi:10.20944/preprints202309.1653.v2
Pons, G., Zarzosa, P., Gallo-Oller, G., Wenz, A. S., Lapins, M., García-Gilabert, L., Sansa-Girona, J., Navarro, N., Segura, M. F., Soriano, A., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.12.03.626050
Catizone, A. N. (2020) · Scholars Archive - University at Albany (University at Albany, State University of New York) · doi:10.54014/1be8-k0fr
MTT cell viability, apoptosis detection and xCelligence real-time cell analysis
Bona, A., Moela, P., October, N., & Balemaken Missi, M. (2023) · UpSpace Institutional Repository (University of Pretoria) · doi:10.25403/upresearchdata.22068350
Characterization of the catalytic properties of the ubiquitin ligase E6AP
Müller, F. (2021) · KOPS (University of Konstanz)
Baloche, V. M. D. (2020) · theses.fr (ABES) · doi:10.70675/dbf8523bze81fz4cd8z9f6az8d4db79d8ff0
Siddik, Z. H. (2026) · Biomolecules · doi:10.3390/biom16060800
“G1 arrest alone by MDM2 inhibitors has been observed in both animal tumor models and patients [50,51], resulting in poor/modest antitumor responses that culminate in acquired resistance to the inhibitors in patients through the selection of mutant p53 clones [48,52,53].”
GÜNGÖRDÜ, Ş. (2025) · Bilecik Şeyh Edebali University Institutional Repository
Rusin, M., Krześniak, M., & Łasut-Szyszka, B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27208964
“An extensive review of the effects of nutlin-3a was presented by Kocik et al. [64].”
Metadata
- Authors
- Kocik, J., Machula, M., Wisniewska, A., Surmiak, E., Holak, T. A., & Skalniak, L.
- Affiliations
- Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30–387 Krakow, Poland
- Jagiellonian University (PL)
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2019-07-19
- Volume
- 11
- Issue
- 7
- Pages
- 1014
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC6678622
- OpenAlex
- W2963228228
- Cited by
- 46
- References
- 237
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 11 · 2023: 5 · 2022: 3 · 2021: 9 · 2020: 8
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Narodowe Centrum Nauki (UMO-2016/21/D/NZ7/00596)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Keywords
- p53, MDM2, combination therapy, anticancer activity, apoptosis, TP53 mutation, synergistic effect, cancer therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.